FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:2067-2068 December 19, 2002 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by van de Vijver, M. J. PubMed Citation

Breast cancer affects about 10 percent of women in Western countries and is still a major cause of illness and death. Most patients with lymph-node–negative disease (i.e., with no evidence that cancer cells have spread beyond the primary tumor) can be effectively treated with surgery and local radiation. Patients with more aggressive disease can benefit from adjuvant chemotherapy or hormone therapy and are currently identified according to a combination of criteria^1,2: age, the size of the tumor, axillary-node status, the histologic type and pathological grade of cancer, and hormone-receptor status. The ability of these criteria to predict disease progression . . . [Full Text of this Article]

This article has been cited by other articles:

• Hebert-Croteau, N., Brisson, J., Latreille, J., Rivard, M., Abdelaziz, N., Martin, G. (2004). Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast Cancer. JCO 22: 3685-3693 [Abstract] [Full Text]  
• Amatschek, S., Koenig, U., Auer, H., Steinlein, P., Pacher, M., Gruenfelder, A., Dekan, G., Vogl, S., Kubista, E., Heider, K.-H., Stratowa, C., Schreiber, M., Sommergruber, W. (2004). Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes. Cancer Res. 64: 844-856 [Abstract] [Full Text]